Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.

Ettinger B, San Martin J, Crans G, Pavo I

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research19 Jan 2004Cited by 319 (Europe PMC)

PMID15068497DOI10.1359/jbmr.040117PepBankPUB-15068497

Publisher page PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

2 results from studies that gave the peptide. 2 results from people.

01HumanNon-randomized trialEfficacy outcome
In women previously receiving raloxifene, teriparatide increased total hip BMD 1.8% from baseline at 18 months.
In plain wordsIn women previously receiving raloxifene, teriparatide increased hip bone density from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD change after prior raloxifene
Study
n: not reported in source
Comparator
Baseline
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · subcutaneous · 18 monthsAs given in this study (human).
Measurements
Total hip BMD increase
1.8%
prior raloxifene, 18 months, versus baseline
Source sentences
Summary
Furthermore, at 18 months, mean total hip BMD had significantly increased (1.8%, p < 0.05) in prior RLX patients but was not different from baseline in prior ALN patients.
2 context sentences(design, population, supporting numbers)
Summary · context
Daily subcutaneous injections of 20 microg teriparatide were administered for 18 months to 59 postmenopausal women, 60-87 years of age, with BMD T-scores </= -2.0 who had previously received either alendronate (ALN) or raloxifene (RLX) therapy for 18-36 months.
Summary · context
All patients received daily calcium (1000 mg) and vitamin D (400 IU) supplementation.
Report a problemFND-1506849708
02HumanNon-randomized trialEfficacy outcome
In women previously receiving alendronate, total hip BMD with teriparatide did not differ from baseline at 18 months.
In plain wordsIn women previously receiving alendronate, hip bone density with teriparatide did not differ from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTotal hip BMD change after prior alendronate
Study
n: not reported in source
Comparator
Baseline
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · subcutaneous · 18 monthsAs given in this study (human).
Source sentences
Summary
Furthermore, at 18 months, mean total hip BMD had significantly increased (1.8%, p < 0.05) in prior RLX patients but was not different from baseline in prior ALN patients.
2 context sentences(design, population, supporting numbers)
Summary · context
Daily subcutaneous injections of 20 microg teriparatide were administered for 18 months to 59 postmenopausal women, 60-87 years of age, with BMD T-scores </= -2.0 who had previously received either alendronate (ALN) or raloxifene (RLX) therapy for 18-36 months.
Summary · context
All patients received daily calcium (1000 mg) and vitamin D (400 IU) supplementation.
Report a problemFND-1506849709

Studies that did not test the peptide alone7

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

03HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women receiving teriparatide, early spine BMD increased 5.2% after prior raloxifene versus 0.5% after prior alendronate.
In plain wordsIn women receiving teriparatide, early spine bone density increased more after prior raloxifene than after prior alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSpine BMD change over first 6 months
Study
n = 59
Comparator
Prior alendronate group
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Measurements
Spine BMD change, first 6 months
5.2%
prior raloxifene group
Spine BMD change, first 6 months
0.5%
prior alendronate group
Source sentences
Summary
During the first 6 months, there were statistically significant (p < 0.05) group differences in BMD change at the hip (prior ALN -1.8% versus prior RLX +0.5%) and at the spine (prior ALN +0.5% versus prior RLX +5.2%).
2 context sentences(design, population, supporting numbers)
Summary · context
Daily subcutaneous injections of 20 microg teriparatide were administered for 18 months to 59 postmenopausal women, 60-87 years of age, with BMD T-scores </= -2.0 who had previously received either alendronate (ALN) or raloxifene (RLX) therapy for 18-36 months.
Summary · context
All patients received daily calcium (1000 mg) and vitamin D (400 IU) supplementation.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1506849704
04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women receiving teriparatide, positive spine BMD slopes were similar after prior raloxifene and prior alendronate between 6 and 18 months.
In plain wordsIn women receiving teriparatide, later spine bone density increases were similar after prior raloxifene and prior alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeLumbar spine BMD slope from 6 to 18 months
Study
n = 59
Comparator
Prior alendronate group
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The positive slopes in hip and lumbar spine BMD were similar in both groups between 6 and 18 months.
2 context sentences(design, population, supporting numbers)
Summary · context
Daily subcutaneous injections of 20 microg teriparatide were administered for 18 months to 59 postmenopausal women, 60-87 years of age, with BMD T-scores </= -2.0 who had previously received either alendronate (ALN) or raloxifene (RLX) therapy for 18-36 months.
Summary · context
All patients received daily calcium (1000 mg) and vitamin D (400 IU) supplementation.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1506849706
05HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women receiving teriparatide, spine BMD increased 10.2% after prior raloxifene versus 4.1% after prior alendronate at 18 months.
In plain wordsIn women receiving teriparatide, spine bone density increased more after prior raloxifene than after prior alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD change at 18 months
Study
n = 59
Comparator
Prior alendronate group
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Measurements
Lumbar spine BMD change at 18 months
10.2%
prior raloxifene group
Lumbar spine BMD change at 18 months
4.1%
prior alendronate group
Source sentences
Summary
After 18 months, mean lumbar spine BMD increased 10.2% in prior RLX compared with 4.1% in prior ALN (p < 0.05) patients.
2 context sentences(design, population, supporting numbers)
Summary · context
Daily subcutaneous injections of 20 microg teriparatide were administered for 18 months to 59 postmenopausal women, 60-87 years of age, with BMD T-scores </= -2.0 who had previously received either alendronate (ALN) or raloxifene (RLX) therapy for 18-36 months.
Summary · context
All patients received daily calcium (1000 mg) and vitamin D (400 IU) supplementation.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1506849707
06HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women receiving teriparatide, bone markers increased earlier after prior raloxifene than after prior alendronate.
In plain wordsIn women receiving teriparatide, bone markers increased earlier after prior raloxifene than after prior alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone marker response timing
Study
n = 59
Comparator
Prior alendronate group
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
During teriparatide treatment, bone markers in prior ALN patients increased later and peaked at about one-third lower levels compared with prior RLX patients.
2 context sentences(design, population, supporting numbers)
Summary · context
Daily subcutaneous injections of 20 microg teriparatide were administered for 18 months to 59 postmenopausal women, 60-87 years of age, with BMD T-scores </= -2.0 who had previously received either alendronate (ALN) or raloxifene (RLX) therapy for 18-36 months.
Summary · context
All patients received daily calcium (1000 mg) and vitamin D (400 IU) supplementation.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1506849701
07HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women receiving teriparatide, peak bone marker levels were higher after prior raloxifene than after prior alendronate.
In plain wordsIn women receiving teriparatide, bone markers reached higher levels after prior raloxifene than after prior alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePeak bone marker response
Study
n = 59
Comparator
Prior alendronate group
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
During teriparatide treatment, bone markers in prior ALN patients increased later and peaked at about one-third lower levels compared with prior RLX patients.
2 context sentences(design, population, supporting numbers)
Summary · context
Daily subcutaneous injections of 20 microg teriparatide were administered for 18 months to 59 postmenopausal women, 60-87 years of age, with BMD T-scores </= -2.0 who had previously received either alendronate (ALN) or raloxifene (RLX) therapy for 18-36 months.
Summary · context
All patients received daily calcium (1000 mg) and vitamin D (400 IU) supplementation.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1506849702
08HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women receiving teriparatide, early hip BMD changed by +0.5% after prior raloxifene versus -1.8% after prior alendronate.
In plain wordsIn women receiving teriparatide, early hip bone density changed more favorably after prior raloxifene than after prior alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseHip BMD change over first 6 months
Study
n = 59
Comparator
Prior alendronate group
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Measurements
Hip BMD change, first 6 months
0.5%
prior raloxifene group
Hip BMD change, first 6 months
−1.8%
prior alendronate group
Source sentences
Summary
During the first 6 months, there were statistically significant (p < 0.05) group differences in BMD change at the hip (prior ALN -1.8% versus prior RLX +0.5%) and at the spine (prior ALN +0.5% versus prior RLX +5.2%).
2 context sentences(design, population, supporting numbers)
Summary · context
Daily subcutaneous injections of 20 microg teriparatide were administered for 18 months to 59 postmenopausal women, 60-87 years of age, with BMD T-scores </= -2.0 who had previously received either alendronate (ALN) or raloxifene (RLX) therapy for 18-36 months.
Summary · context
All patients received daily calcium (1000 mg) and vitamin D (400 IU) supplementation.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1506849703
09HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women receiving teriparatide, positive hip BMD slopes were similar after prior raloxifene and prior alendronate between 6 and 18 months.
In plain wordsIn women receiving teriparatide, later hip bone density increases were similar after prior raloxifene and prior alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeHip BMD slope from 6 to 18 months
Study
n = 59
Comparator
Prior alendronate group
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The positive slopes in hip and lumbar spine BMD were similar in both groups between 6 and 18 months.
2 context sentences(design, population, supporting numbers)
Summary · context
Daily subcutaneous injections of 20 microg teriparatide were administered for 18 months to 59 postmenopausal women, 60-87 years of age, with BMD T-scores </= -2.0 who had previously received either alendronate (ALN) or raloxifene (RLX) therapy for 18-36 months.
Summary · context
All patients received daily calcium (1000 mg) and vitamin D (400 IU) supplementation.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1506849705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.